Actionable trade ideas with defined risk and time horizons.
Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.
10,956 total articles
Amazon's AWS looks positioned to fold OpenAI-model access and Nvidia GPU economics into a unified enterprise stack, cutting Anthropic out of critical enterprise lanes. This trade targets a re-rating driven by higher AI-related revenue capture and improved incremental margins. Entry, stop and target are laid out with a clear 180-trading-day horizon …
HydroGraph Clean Pwr (HGRAF) is an OTC micro-cap developing graphene-related technology. Price action and volume have picked up in March 2026 while technicals show a mixed picture. This trade idea outlines a long-biased plan with clear entry, stop and target levels, and a risk-minded view appropriate for an OTC play with limited public disclosures.
Novo Nordisk looks dangerously exposed: cheap semaglutide generics from India, a troubled pipeline headline and stretched capital-market expectations have already crushed the stock from a $81 52-week high to the mid-$30s. Combine a heavy institutional short interest, weakening technicals and near-term legal/regulatory headlines, and you have a trad…
Fortinet's combination of durable free cash flow ($2.23B), high retention and recent revenue acceleration (15.1% reported for Q4 2025), and product roadmaps layered with AI capabilities argue for upside from current levels. Valuation is full but not irrational: market cap roughly $61B, P/E around 33x and P/FCF near 27x. This trade targets near-term…
Palantir remains a conviction long despite headline risks. This trade idea lays out an actionable swing plan with an entry, stop, and target, plus the fundamental rationale, catalysts, and the specific risks that would force me to change my view.
Micron is the biggest pure-play memory beneficiary of an HBM shortage tied to AI infrastructure. Strong revenue/earnings beats, robust free cash flow and low leverage support a bull case that could take the stock to ~$890 (implied $1T market cap). Trade plan provided with entry at $416.00, stop at $360.00 and a long-term target of $890.00 (180 trad…
PayPal is trading at roughly an 8x P/E with robust free cash flow and an enterprise value to EBITDA near 6x. Recent governance shocks and a class-action filing have left the stock cheap. This trade idea lays out a clear entry, stop and target with a 180-trading-day horizon and balanced risk framework.
Microsoft's deep cloud footprint and suite of AI products make it the most likely beneficiary if 'agentic' AI adoption accelerates across enterprises. Recent data showing a 466.7% YoY increase in enterprise AI agents underscores the scale of the opportunity and the security tailwind that should push Azure, M365 Copilot, and security subscriptions h…
Microsoft ($MSFT) has been marked down with the broader tech selloff, but fundamentals remain intact: $77.4B of free cash flow, ROE ~30.5%, and a strong balance sheet (debt/equity ~0.10). Technicals show short-term oversold conditions (RSI ~36) while valuations (PE ~23.9, P/FCF ~36.6) still price in growth. This trade idea advocates a mid-term long…
Palantir's share move after Wedbush reiteration and a 5% pop shows market sensitivity to headline risk. The real business - mission-critical deployments, long-duration government contracts and platform-led commercial traction - is poorly captured by single-model competition narratives (Anthropic). We favor a long trade targeting the $230 analyst le…
PayPal's stock trades like a company in distress while its cash generation and balance-sheet metrics still look solid. With a market cap near $42B, free cash flow of $5.56B and an implied P/E around 8, we think a measured long makes sense. This trade bets on valuation mean reversion, stabilization under new management and a de-risking of the litiga…
Palisade Bio is an underfollowed clinical-stage biotech developing oral therapies for post-operative and inflammatory gut disorders. With a market cap near $281M, ~ $28.8M in cash, a Canadian patent allowance for its PALI-2108 candidate, and Phase 1 expected progress, the risk/reward skews toward upside for catalytic readouts. Initiate a speculativ…
HENSOLDT (HAGHY) has been marked down with the broader defense swoon, but the company's backlog exposure, JV pipeline in additive electronics, and attractive entry near $8.75 make a tactical long compelling. We lay out a mid-term (45 trading days) trade with clear entry, stop, and target, plus catalysts and risk controls.
Trican's recent execution—tight cost control, higher activity in core basins, and improved pricing on completion services—sets the stage for cash flow expansion. With limited near-term headline risk and a clear path to deleveraging, this trade targets a rebound backed by cash generation rather than multiple expansion. Entry $1.20, target $2.50, sto…
Clearwater Analytics (CWAN) is currently trading below the $24.55 per-share buyout price agreed with Permira and Warburg Pincus. With deal terms public, activist support in the shareholder base and limited near-term execution risk, a long arbitrage-sized position at the current market price offers a modest absolute return and ~17% annualized upside…
Golar LNG (GLNG) combines long-duration charter backlog, operational FSRU/FLNG assets, and recent contract wins that make it a leveraged way to play higher LNG flows and rerouting after the Iran conflict. The company is capitalized at roughly $5.4B and carries near-term catalysts that can re-rate the stock, but leverage, negative EPS and project ex…
GDS has cleared a series of operational boxes — C-REIT progress, a $385M DayOne monetization and apparent post-earnings strength that the market is treating as an EBITDA beat plus improving pricing power. At a $9.41B market cap and with technicals showing bullish momentum, we lay out a mid-term trade: entry $43.20, stop $40.50, target $48.00 (about…
Jerónimo Martins looks increasingly exposed to margin compression from intensified competition in Poland, normalization of consumer spending patterns, and promotional mix shifts. We recommend a tactical short with a mid-term horizon to capture an anticipated re-rating as margins reset.
Thomson Reuters (TRI) has been punished this year even as its core Legal, Tax & Accounting, and Corporate content businesses continue to produce recurring revenue and pricing power. At a $40.3B market cap, 2.6% yield and a trailing P/E near 28, the stock looks mispriced relative to the durability of its cash flows and the optionality in AI-enabled …
Rubrik just delivered a quarter that beats on revenue and EPS, and its free cash flow is accelerating. The market has punished software names on AI disruption fears, but Rubrik's data-resilience positioning and a $238M quarterly free cash flow print argue for buying the pullback. This trade plan defines entry, stop and target for a mid-term window …
Nano Labs is trading at a tiny $72M market cap after a 2025 strategic pivot to crypto reserves and major expense cuts. The stock is cheap on simple book metrics and has a catalyst-rich runway (new hardware, BNB-focused programs, insider buying). This trade idea takes a tactical long position into the next earnings/operational update with defined en…
General Mills is trading at multi-year lows with a rich dividend, low P/E and an oversold technical backdrop. This trade idea argues for a phased accumulation with defined risk parameters: initial entry at $36.50, stop loss at $34.00 and a primary target of $46.00. The setup favors investors seeking income and value with a long-term horizon, while …
Axcelis Technologies (ACLS) is a capital-equipment beneficiary of the next memory capacity cycle and stands to gain scale if its pending Veeco merger closes. The company trades at a reasonable multiple, has strong cash generation and a light balance sheet. This trade idea lays out an actionable long with entry, stop and target tied to milestones an…
Micron is priced like a fast-grower but delivering the profitability and balance-sheet strength to justify it. At $428, the stock trades at ~20x forward earnings with 33% ROE, low leverage, and $10.3B of free cash flow. If AI demand and HBM tightness persist, the multiple can hold or expand; if capacity comes online and margins compress, downside i…
Goldman Sachs (GS) has pulled back roughly 20% from recent highs, dragging the stock into a valuation that looks attractive relative to earnings and book value. We lay out a mid-term trade: entry at $835.00, stop at $795.00, target $960.00, and a 45-trading-day horizon. The trade leans on a favorable P/E (~15), healthy ROE (13%), and demonstrable t…
